Onco-Innovations Signs LOI with Nanosoft Polymers to Advance Polymer and Drug Delivery Development for the ONC010 Program

Executive Summary

• Onco-Innovations Limited announced a non-binding Letter of Intent (LOI) with Nanosoft Polymers to negotiate a services agreement focused on polymer process development, analytical characterization, and drug formulation optimization for its ONC010 PNKP Inhibitor Technology.
• The company simultaneously appointed Dave Antony as Vice President of Corporate Finance to strengthen financial planning, governance, and capital markets advisory capabilities.
• The LOI is preliminary and non-binding with no certainty of a definitive agreement, but aims to advance scalability, reproducibility, and regulatory readiness for ONC010's clinical development pathway.

Key Details

• LOI Scope & Activities: Proposed negotiations will cover polymer synthesis, process optimization, analytical characterization methodology support, formulation optimization, encapsulated API development support, and process transfer planning for potential future GMP manufacturing.
• Counterparty Expertise: Nanosoft Polymers specializes in functional polymers and copolymers for drug delivery. Led by Dr. Xiaobing Xiong, who co-invented Onco's patented nano delivery system alongside Dr. Afsaneh Lavasanifar (University of Alberta).
• Binding Status: The LOI is explicitly non-binding, and there is no certainty that a definitive services agreement will be executed.
• Management Appointment: Dave Antony appointed as Vice President of Corporate Finance, bringing over 35 years of experience in financial planning, reporting, corporate governance, and public company advisory.
• Antony's Background: Former Chairman of the TSXV Advisory Committee for Alberta and member of the TSXV National Advisory Committee, with extensive capital markets and exchange-related advisory experience across health, technology, natural resources, and regulated gaming sectors.
• Strategic Rationale: The partnership is intended to build the technical framework around ONC010, supporting scalability, reproducibility, and regulatory readiness for future clinical and regulatory development activities.

Notable Quotes

• Thomas O'Shaughnessy, CEO: "This LOI with Nanosoft represents a solid preliminary step as we continue building the technical framework around ONC010. Polymer engineering and nanoparticle formulation are important components of our development pathway, and the proposed relationship with Nanosoft is intended to support further planning around scalability, reproducibility and regulatory readiness."
• Dr. Islam Mohamed, CMO: "The development of nanoparticle-based oncology therapeutics requires careful integration of polymer science, formulation engineering and analytical characterization. Dr. Xiong's prior experience with the Company's proprietary nano delivery system, together with Nanosoft's polymer-focused expertise, provides a strong basis for the proposed relationship contemplated by the LOI as we continue preparing ONC010 for future clinical and regulatory development activities."